|
Autism Spectrum Disorders
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
A study of single nucleotide polymorphisms in CD157, AIM2 and JARID2 genes in Han Chinese children with autism spectrum disorder.
|
29216786 |
2018 |
|
Autism Spectrum Disorders
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The analysis using the posterior probability of membership to an LC detected an association in the JARID2 gene as significant as that for ASD (P = 3 × 10(-5)) but with a larger effect size (odds ratio = 2.17 vs. 1.55).
|
21308764 |
2011 |
|
Autism Spectrum Disorders
|
0.320 |
Biomarker
|
disease |
CTD_human |
The analysis using the posterior probability of membership to an LC detected an association in the JARID2 gene as significant as that for ASD (P = 3 × 10(-5)) but with a larger effect size (odds ratio = 2.17 vs. 1.55).
|
21308764 |
2011 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
This was not replicates in the extended sample, we conclude that JARID2 could be a susceptibility gene for SZ.
|
19884986 |
2009 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Consequently, we explored the possibility that JARID2 itself could be a candidate gene for 6p22.3-linked SZ.
|
16967465 |
2007 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
LHGDN |
Consequently, we explored the possibility that JARID2 itself could be a candidate gene for 6p22.3-linked SZ.
|
16967465 |
2007 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Consequently, we explored the possibility that JARID2 itself could be a candidate gene for 6p22.3-linked SZ.
|
16967465 |
2007 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Our discovery of a previously unidentified miR-34a/miR-7/JARID2 pathway controlling dihydroartemisinin effects on Axl expression and inhibition of cancer cell proliferation, migration, invasion, and tumor formation provides new molecular mechanistic insights into dihydroartemisinin anticancer effect on prostate cancer with potential therapeutic implications.
|
30783079 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Finally, we show that JARID2 and SFRP1 are inversely correlated in melanoma, confirming that the JARID2-mediated repression of SFRP1 extends beyond skeletal muscle and has important implications in many cellular systems, including cancer.
|
30119689 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In B-CLL cells, some remarkable unique features like the loss of tumor suppressor molecules PNN and JARID2, the stress-related serotonin transporter SLC6A4, and high expression of ZNF207, CCDC88A, PIGR and ID3, otherwise associated with stem cell phenotype, were determined.
|
29196338 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In this study, genetic mouse models and patient-derived xenografts demonstrated that JARID2 acts as a tumor suppressor in chronic myeloid disorders.
|
30423295 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Jarid2 is implicated in signaling pathways regulating cancer cell epithelial-mesenchymal transition, and stem cell maintenance.
|
28445934 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Jumonji AT-rich interactive domain 2 (JARID2) is a member of the Jumonji family of proteins and has been proposed as an oncogene in several types of human cancer.
|
27641964 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer.
|
28445934 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Knockdown of JARID2 obviously inhibits the proliferation of U87MG cells and tumor growth in vivo.
|
27641964 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings indicate that JARID2 is a negative regulator of leukemia cell proliferation, and functions as potential tumor suppressor in leukemia.
|
25939703 |
2015 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
|
22190018 |
2012 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Our discovery of a previously unidentified miR-34a/miR-7/JARID2 pathway controlling dihydroartemisinin effects on Axl expression and inhibition of cancer cell proliferation, migration, invasion, and tumor formation provides new molecular mechanistic insights into dihydroartemisinin anticancer effect on prostate cancer with potential therapeutic implications.
|
30783079 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Finally, we show that JARID2 and SFRP1 are inversely correlated in melanoma, confirming that the JARID2-mediated repression of SFRP1 extends beyond skeletal muscle and has important implications in many cellular systems, including cancer.
|
30119689 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Jarid2 is implicated in signaling pathways regulating cancer cell epithelial-mesenchymal transition, and stem cell maintenance.
|
28445934 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Jumonji AT-rich interactive domain 2 (JARID2) is a member of the Jumonji family of proteins and has been proposed as an oncogene in several types of human cancer.
|
27641964 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
However, little is known about the role of JARID2 in the metastasis of placenta trophoblast cells.
|
28714012 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Protein Jumonji (JARID2), a member of the family of JmjC domain-containing proteins, has been reported to serve an important role in tumor growth and metastasis.
|
28765957 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In conclusion the observations suggested that knockdown of JARID2 inhibited proliferation, migration and invasion in vitro through the inactivation of the PI3K/Akt signaling pathway.
|
28765957 |
2017 |